baloxavir marboxil   Click here for help

GtoPdb Ligand ID: 11748

Synonyms: S-033188 | S033188 | Xofluza®
Approved drug
baloxavir marboxil is an approved drug (Japan & FDA (2018), EMA (2021))
Compound class: Synthetic organic
Comment: Baloxavir marboxil is an orally delivered anti-influenza virus drug. It is a prodrug that is converted to baloxavir [1]. Mechanistically baloxavir is a first-in-class inhibitor of the cap-endonuclease (CEN) activity of an acidic protein within the viral polymerase complex [3] that is essential for viral gene transcription and replication. Alternative influenza antivirals (e.g. oseltamivir, peramivir and zanamivir) target the neuraminidase enzyme that is required for fusion and entry of virus into the host cells, and the budding process that releases newly synthesised virions.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 124.84
Molecular weight 571.12
XLogP 4.13
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC(=O)OCOc1c(=O)ccn2c1C(=O)N1CCOC[C@H]1N2[C@@H]1c2ccccc2SCc2c1ccc(c2F)F
Isomeric SMILES COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N(n2ccc1=O)[C@H]1c2c(CSc3ccccc13)c(c(cc2)F)F
InChI InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1
InChI Key RZVPBGBYGMDSBG-GGAORHGYSA-N
References
1. Abraham GM, Morton JB, Saravolatz LD. (2020)
Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza.
Clin Infect Dis, 71 (7): 1790-1794. [PMID:32020174]
2. Ivashchenko AA, Mitkin OD, Jones JC, Nikitin AV, Koryakova AG, Ryakhovskiy A, Karapetian RN, Kravchenko DV, Aladinskiy V, Leneva IA et al.. (2020)
Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses.
J Med Chem, 63 (17): 9403-9420. [PMID:32787099]
3. Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, Kuwahara T, Kishida N, Watanabe S, Odagiri T. (2018)
Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.
Front Microbiol, 9: 3026. [PMID:30574137]